FDA Accepts New Drug Application for 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer Treatment

Phase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)